Nasjonal faglig retningslinje for utredning, behandling og oppfølging av personer med psykoselidelser

300. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, et al. Striatal vs
extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind
PET study in schizophrenia. Neuropsychopharmacology 2007;32(6):1209-15.

301. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical
antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry
2001;50(11):873-83.

302. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and
effectiveness to clinical decision-making. Can J Psychiatry 2010;55(3):117-25.

303. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus
first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009;373(9657):31-41.

3 04. Høiseth G, Bentsen H. Bruk av antipsykotiske depotinjeksjoner. Tidsskr Nor
Legeforen 2012;132(3):301-3.

305. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide
cohort study of oral and depot antipsychotics after first hospitalization for
schizophrenia. Am J Psychiatry 2011;168(6):603-9.

306. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of
tardive dyskinesia with risperidone or olanzapine in the elderly: results from a
2-year, prospective study in antipsychotic-naive patients.
Neuropsychopharmacology 2011;36(8):1738-46.

307. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from
receptor-binding profiles. Mol Psychiatry 2008;13(1):27-35.

308. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates
and suspects. Curr Drug Saf 2010;5(1):97-104.

309. Forskrift om legemidler (legemiddelforskriften). FOR 2009-12-18 nr 1839.

310. Bivirkninger [nettdokument]. s.l.: Relis [oppdatert 25. Feb 2013; lest 26. Feb
2013]. Tilgjengelig fra: http://www.relis.no/bivirkninger

311. Oosthuizen P, Emsley RA, Turner J, Keyter N. Determining the optimal dose of
haloperidol in first-episode psychosis. J Psychopharmacol 2001;15(4):251-5.

312. interaksjoner.no [database]. Oslo: Statens legemiddelverk [oppdatert 2013; lest
28. Feb 2013]. Tilgjengelig fra: http://www.interaksjoner.no/

313. Nasjonalt informasjonssenter for alternativ behandling [nettdokument]. Oslo:
Nifab [oppdatert 2013; lest 28. Feb 2013]. Tilgjengelig fra: http://www.nifab.no/

314. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized
controlled trial of the effect on Quality of Life of second- vs first-generation
antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs
in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87.

315. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl
J Med 2005;353(12):1209-23.

316. Kissling W. The current unsatisfactory state of relapse prevention in schizophrenic
psychoses--suggestions for improvement. Clin Neuropharmacol 1991;14(Suppl
2):S33-S44.

REFERANSER 201

317. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of
relapse following response from a first episode of schizophrenia or schizoaffective
disorder. Arch Gen Psychiatry 1999;56(3):241-7.

318. Barnes TR. Evidence-based guidelines for the pharmacological treatment
of schizophrenia: recommendations from the British Association for
Psychopharmacology. J Psychopharmacol 2011;25(5):567-620.

319. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy
of schizophrenia. Int J Neuropsychopharmacol 2011;14(2):269-84.

320. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for
people with schizophrenia already stable on chlorpromazine. Cochrane Database
Syst Rev 2007;(1):CD006329.

321. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice
guidelines: international survey and comparison. Br J Psychiatry 2005;187:248-55.

322. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided
discontinuation versus maintenance treatment in remitted first-episode
psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007;68(5):­
654-61.

323. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al.
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent
drug treatment with prodrome-based early intervention: results of a randomized
controlled trial within the German Research Network on Schizophrenia. J Clin
Psychiatry 2011;72(2):205-18.

324. Gillies D, Beck A, McCloud A, Rathbone J, Gillies D. Benzodiazepines alone or in
combination with antipsychotic drugs for acute psychosis. Cochrane Database
Syst Rev 2005;(4):CD003079.

325. Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for
psychosis-induced aggression. Cochrane Database Syst Rev 2009;(3):CD005146.

326. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated
people with suspected serious mental illnesses. Cochrane Database Syst Rev
2005;(2):CD003729.

327. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia.
Schizophr Bull 1997;23(4):663-74.

328. Lambert M, Naber D, Schacht A, Wagner T, Hundemer HP, Karow A, et al. Rates and
predictors of remission and recovery during 3 years in 392 never-treated patients
with schizophrenia. Acta Psychiatr Scand 2008;118(3):220-9.

329. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders:
a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24(1):75-85.

330. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a
clinical review of adverse effects and management. Ann Clin Psychiatry
2003;15(1):33-48.

331. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized
controlled trial of effect of prescription of clozapine versus other second-
generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull
2006;32(4):715-23.

202  REFERANSER

332. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin
Psychiatry 2003;64(9):984-9.

333. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin
Psychiatry 2010;23(2):103-11.

334. Kyung LE, Douglass AB. Sleep in psychiatric disorders: where are we now? Can J
Psychiatry 2010;55(7):403-12.

335. Gjerden P, Slørdal L, Bramness JG. Association between the use of anticholinergic
antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic
agents. Eur J Clin Pharmacol 2009;65(12):1229-35.

336. Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: II. Withdrawal after long-
term maintenance therapy. J Clin Pharmacol 1991;31(8):769-77.

337. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia.
Cochrane Database Syst Rev 2007;(1):CD006391.

338. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst
Rev 2007;(3):CD003834.

339. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia.
Cochrane Database Syst Rev 2007;(3):CD001258.

3 40. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database
Syst Rev 2008;(3):CD004028.

341. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both
schizophrenia and depression. Cochrane Database Syst Rev 2002;(2):CD002305.

342. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for
schizophrenia. Cochrane Database Syst Rev 2006;3:CD001257.

343. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane
Database Syst Rev 2005;(2):CD000076.

344. Correll CU. Addressing adverse effects of antipsychotic treatment in young
patients with schizophrenia. J Clin Psychiatry 2011;72(1):e01.

345. Meyers BS, Jeste DV. Geriatric psychopharmacology: evolution of a discipline. J Clin
Psychiatry 2010;71(11):1416-24.

3 46. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of
olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med
Assoc Thai 2005;88(Suppl 3):S43-S52.

347. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane
Database Syst Rev 2009;(1):CD003026.

348. Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, et al. Pharmacological
treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs
2008;22(11):903-16.

349. Hjorthoj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in
people with schizophrenia spectrum disorders - a systematic review. Addict Behav
2009;34(6-7):520-5.

350. Webb RT, Howard L, Abel KM. Antipsychotic drugs for non-affective psychosis
during pregnancy and postpartum. Cochrane Database Syst Rev
2004;(2):CD004411.

REFERANSER 203